robert henric
posted a blog.
According to the new market research report "Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) - Global Forecast to 2027", published by MarketsandMarkets™, the Cold Pain Therapy Market was valued at USD 1.8 billion in 2022 and is projected to reach USD 2.4 billion by 2027 growing at a CAGR of 5.1%.
Browse in-depth TOC on "Cold Pain Therapy Market"243 – Tables42 – Figures249 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55543905
The rising awareness about the cost-effective cold pain relief products, and rising prevalence of arthritis. Emerging economies such as China, Japan, and India are providing profitable opportunities for the players operating in the market.
The OTC products segment accounted for the largest share of the cold pain therapy market, by product segment, in 2021
The market is segmented into OTC products and prescription products. The OTC products holds the largest share of the market in 2021, mainly due to the presence of substantial clinical evidence in favor of cooling gels as sports medicine.
Musculoskeletal disorders segment to register the highest growth rate during the forecast period
The cold pain therapy market has been segmented into musculoskeletal disorders, sports medicine, post-operative therapy, and post-trauma therapy. In 2021, the musculoskeletal disorders segment accounted for the largest share of the market. Factors such as rising geriatric population due to which there is higher prevalence of musculoskeletal disorders and increasing self-care awareness will drive the growth of this segment.
The retail pharmacies segment accounted for the largest share of the cold pain therapy, by distribution channel segment, in 2021
Based on the distribution channel, the cold pain therapy market has been segmented into hospital pharmacies, retail pharmacies, and e-pharmacies. In 2021, the retail pharmacies segment accounted for the largest share of the market. The implementation of government regulations for proper functioning of retail pharmacies is driving the growth of this segment.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=55543905
North America is the largest regional market for cold pain therapy market
The global cold pain therapy market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the market. The North American market growth can be attributed to the growing incidence of arthritis.
The major players operating in this cold pain therapy market are Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=55543905
Be the first person to like this.
robert henric
posted a blog.
Growth Factors Driving the Market: The Point of Care Diagnostics Market growth is mainly driven by the high prevalence of infectious diseases, supportive government policies and rising number of CLIA-waived POC tests. In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market. However, issues related to pricing pressure owing to reimbursement cuts and budget constraints are expected to hinder the growth of the point of care diagnostics market during the forecast period.
MarketsandMarkets™ View on Revenue: The global point of care and rapid diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.
Industry Segmentation in Detailed:
The Glucose Monitoring Products segment accounted for the largest share of the point of care diagnostics market.
Based on products, the point-of-care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products. In 2021, the glucose monitoring products segment accounted for the largest share of the point-of-care diagnostics market. This can be attributed to the growing diabetic patient population base, ongoing technological advancements, and the growing preference for home glucose testing.
The Lateral Flow Assays segment accounted for the largest share of the poc diagnostics market.
Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The widespread adoption of lateral flow assays in POC testing as a replacement for lengthy, conventional laboratory procedures is a key factor contributing to the growth of this segment.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185
Leading Key Players Analysis:
Prominent players in the point-of-care diagnostics market include Abbott Laboratories (US), Siemens Healthineers AG (Germany), Quidel Corporation (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux S.A. (France)
Geographical Trends in Detailed:
The global point of care diagnostics market is segmented into North America (comprising the US and Canada), Europe (includes Germany, France, and the UK), the Asia Pacific (includes Japan, China, India), Latin America (Brazil, Mexico), and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases, growing number of product approvals, and government initiatives to support the wider adoption of POC testing products are the key factors driving the growth of the North American point-of-care diagnostics market.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185
Be the first person to like this.
robert henric
posted a blog.
Growth Factors Driving the Market: The high prevalence of infectious diseases worldwide, rapid growth in the geriatric population, growing demand for point-of-care testing, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. On the other hand, reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key restraints.
The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries. In addition, recent outbreaks of infectious diseases from the spread of viruses (such as Ebola, H1N1, and Zika) have highlighted the need for early disease detection capabilities, which is also expected to drive market growth. The current COVID-19 pandemic has resulted in high demand for rapid diagnostic testing through lateral flow technology, supporting the growth of this market in the coming year.
Be the first person to like this.
robert henric
posted a blog.
Growth Factors Driving the Market: The emergence of 3D-printed implants can provide significant opportunities for market growth. German companies, BellaSeno and Evonik, have entered into a collaboration to develop 3D breast implant technology. BellaSeno will use Evonik’s Resomer bioresorbable polymer in its Senella breast scaffolds, avoiding the use of silicone implants that have raised major safety concerns.
BellaSeno planned to start the first human clinical trials of the Senella scaffolds with Resomer in Germany in 2019. Evonik has supplied its Resomer polymer for clinical and commercial use. The scaffolds are designed to guide the growth of the natural tissue using the patient's body fat harvested via liposuction. This product is designed to be used after augmentation, reconstruction, and revision surgery. This is progressively reabsorbed by the body and replaced with natural breast tissue. This technology avoids the use of silicone implants and their associated complications & risk, like capsular contracture, rupture, and deflation. Moreover, in December 2021, Bellaseno GmbH reported the publication of first-in-human data for its 3D-printed biodegradable and highly porous Senella scaffold filled with an autologous fat graft to correct a chest deformation in a 22-year-old patient with severe pectus excavatum. The article was published in the European Journal of Plastic Surgery.
MarketsandMarkets™ View on Revenue: The global breast reconstruction market size is expected to grow from USD 647 million by 2026 to USD 567 million in 2021, at a CAGR of 2.7%.
Industry Segmentation in Detailed:
"Breast implants accounted for the largest share of the breast reconstruction market"
Based on the product, the breast reconstruction market is segmented into breast implants, tissue expanders, and acellular dermal matrix. The breast implants segment accounted for the largest market share in 2020.
"The immediate procedures segment accounted for the largest market share in 2020."
Based on the procedure, the breast reconstruction market is segmented into immediate, delayed, and revision procedures. The immediate procedures segment accounted for the largest market share in 2020. This is primarily attributed to the increasing number of surgeries post-mastectomy and rising awareness.
"The unilateral segment accounted for the largest market share in 2020."
Based on type, the breast reconstruction market is segmented into unilateral and bilateral. The unilateral segment accounted for the largest market share in 2020. The increasing incidence of breast cancer and rising awareness are major factors responsible for the dominant share of this segment.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186501593
Leading Key Players Analysis:
The prominent players operating in this market include Mentor Worldwide LLC (Johnson & Johnson) (US), are Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), Silimed (Brazil), Laboratories Arion (France), and other players are Guangzhou Wanhe Plastic Materials Co. Ltd.(China), CEREPLAS (France), HansBiomed (South Korea), PMT Corporation (US), and Shanghai Kangning Medical Device (China)
Mentor Worldwide LLC (Johnson & Johnson) (US) is one of the leading players in the breast reconstruction market. The company offers a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the breast reconstruction market.
Geographical Trends in Detailed:
North America was the largest regional market for breast reconstruction in 2020;
The breast reconstruction market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2020, North America held the largest share of the market, followed by Europe. The rising incidences of breast cancer, increasing awareness of breast reconstruction, and FDA approvals for breast reconstruction products in this region are the major factors driving the growth of the breast reconstruction in North America.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186501593
Be the first person to like this.
robert henric
posted a blog.
Growth Factors Driving the Market: The In Vivo Toxicology Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine
MarketsandMarkets™ View on Revenue: The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period.
Industry Segmentation in Detailed:
The immunotoxicity segment accounted for the largest share of the in vivo toxicology market.Based on toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment
The chronic test type segment accounted for the largest share of the in vivo toxicology market.Based on test type, the global in vivo toxicology testing market is segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.
The outsourced testing facilities segment accounted for the largest share of the in vivo toxicology market.Based on the testing facility, the global in vivo toxicology market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to dominate the market, by testing facility, over the forecast period. In 2019, the outsourced testing facilities segment held the largest share of the global in vivo toxicology market. The large share of this segment is attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, resulting in increased outsourcing of services to CROs
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105308811
Leading Key Players Analysis:
The major players operating in In Vivo Toxicology Testing Market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.
Geographical Trends in Detailed:
The global in vivo toxicology market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105308811
Be the first person to like this.
robert henric
posted a blog.
Contract Research Organization Services Market - Global Industry Leaders & Growth Strategies Adopted
Growth Factors Driving the Market: The Growth in CRO services market can mainly be attributed to factors such as the increasing investment in pharmaceutical R&D, rising number of clinical trials, high cost of in-house drug development (encouraging pharma-biotech companies to opt for outsourcing), and the rising prevalence of orphan and rare diseases (creating new revenue pockets for CROs). Growth in the drugs and biologics market despite the COVID-19 pandemic, the increasing demand for specialized testing services among end users, and the need for novel clinical trial designs for complex cell and gene therapies are also expected to offer a wide range of growth opportunities to players operating in this market.
MarketsandMarkets™ View on Revenue: The Global Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0% during the forecast period.
Industry Segmentation in Detailed:
The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021.
Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.
The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021.
Based on therapeutic area, the CRO services market is segmented into oncology, infectious diseases, neurology, vaccines, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the global CRO services market in 2021. The large share of this segment is primarily attributed to the increasing number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167410116
Leading Key Players Analysis:
The Asia Pacific region is the fastest-growing region of the CRO services market.
Key players in the global CRO servicesMarket include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc.), ICON plc (Ireland), Charles River Laboratories International, Inc. (US), WuXiAppTec Co., Ltd. (China), Syneos Health Inc. (US), Parexel International Corporation (US).
Geographical Trends in Detailed:
The global CRO services market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The market in the Asia Pacific is estimated to record the highest CAGR during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, increasing number of pharmaceutical companies establishing their manufacturing facilities in the region, and the lower cost of clinical trials in the region.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=167410116
Be the first person to like this.
robert henric
posted a blog.
Growth Factors Driving the Market: The Growth of the Cancer Diagnostics Market is driven mainly by increasing incidence of cancer and growth in the number of private diagnostic laboratories.
In an attempt to detect cancer in the early stages and bring down the mortality rate, governments in developed countries and primary care doctors are recommending cancer screening tests for patients. The US Preventive Services Task Force (USPSTF) recommends screening for colorectal cancer starting at 50 years of age to 75 years of age in the US as a means of preventing disease incidence and ensuring early-stage treatment. Canada has also implemented guidelines for biennial colorectal cancer screening for people aged 50 to 74 years.
MarketsandMarkets™ View on Revenue: The global cancer diagnostics market size was valued at USD 17.2 billion in 2021 and is expected to grow at a CAGR of 11.5%
Industry Segmentation in Detailed:
The consumables segment is expected to grow at the highest CAGR during the forecast period.
Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to witness the highest growth during the forecast period. The repeated purchase and high consumption, and the high prevalence of diseases the major factors supporting the growth of this segment.
The technology segment accounted for the largest share of the cancer diagnostics market.
By technology, the cancer diagnostics market is segmented IVD testing, imaging based and biopsy technique. The IVD testing segment accounted for the largest market share in 2020. The large share of this segment can be attributed to increasing incidence of cancer.
Hospitals for the largest share of the cancer diagnostics market.
Based on end-users, the cancer diagnostics market is segmented into hospitals and diagnostic laboratories. The hospitals segment accounted for the largest share of the cancer diagnostics market in 2020. The increasing number of patients visiting hospitals, rising number of in-house diagnostic procedures performed in hospitals, and growing awareness regarding early diagnosis is are the major driving factor for this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121
Leading Key Players Analysis:
Some of the major players operating in this market are GE Healthcare (US), Roche Diagnostics (Switzerland), and Becton, Dickinson and Company (US). In 2020, GE Healthcare held the leading position in the market. The company has a strong geographic presence across the US, Asia, Europe, Middle East and Africa, & the Americas. Moreover, the company’s strong brand recognition and comprehensive product portfolio in the cancer diagnostics market is its key strength. BD held the second position in the cancer diagnostics market in 2020.
Geographical Trends in Detailed:
The cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the cancer diagnostics market. The large share of North America can be attributed to factors such as the increasing incidences of cancer, growing awareness early diagnosis and technological advancement.
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121
Be the first person to like this.
robert henric
posted a blog.
According to the new market research report “Virology Specimen Collection Market by Product (Viral Transport Media, Swabs, Blood Collection Kits, Specimen Collection Tubes), Sample Type (Blood, Cervical, Nasal, Nasopharyngeal, Throat, Oral), Region-Global Forecast to 2026″, published by MarketsandMarkets™, the global market is projected to reach USD 5.4 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of -0.6%.
Driver: Rising prevalence of viral diseases and emergence of newer pathogens;
The Zika virus and Babesia outbreaks, alongside announcements for their inclusion in virology specimen collection tests, indicate the need for innovation in virology specimen collection technologies, consumables, and instruments. Other countries have also undertaken initiatives to check for new and emerging diseases. For example, the prevalence of malaria in African regions and the possibility of mosquito-borne transfer of Zika has resulted in mandates for Zika virus screening in the region.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150226807
The Rising number of blood donations are among the factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the market.
In 2020, virology transport media segment accounted for the largest share of the virology specimen collection market;
The virology specimen collection market is segmented into viral transport media, swabs, blood collection kits, and specimen collection tubes. The viral transport media accounted for the largest share of the virology specimen collection market in 2020, mainly due to the rising number of blood donations, and the emergence of new pathogens.
In 2020, nasopharyngeal sample segment accounted for the largest share in the market;
The virology specimen collection market is segmented blood, cervical, nasal, nasopharyngeal, throat, oral, and other (conjunctiva, feces, nasopharyngeal aspirate or wash, urethral, urine samples, semen, sputum, and cerebrospinal fluid) samples. In 2020, nasopharyngeal samples accounted for the largest share of the virology specimen collection market. The large share of this segment can be attributed primarily due to the fast detection of transfusion transmissible infection (TTIs), and the increasing prevalence of HPV-related cancers (all cervical cancers) & human papillomavirus (HPV).
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150226807
The global Virology Specimen Collection Market is segmented into four major regions, namely, North America, Europe, the Asia Pacific and Rest of the World. In 2020, North America accounted for the largest share of the market. The large share of this region can be attributed to increasing number of blood donations in the region.
The major players operating in virology specimen collection market are Becton, Dickinson and Company (US), Quidel Corporation (US), Thermo Fisher Scientific, Inc. (US), Trinity Biotech (Ireland), Titan Biotech, Ltd. (India), Diasorin SA (Italy), Vircell S.L. (Spain), Copan Italia S.p.A. (Italy), Puritan Medical Products, Co. (Guilford, ME) and Hardy Diagnostics (US).
Becton, Dickinson and Company is one of the leading company in the market. BD manufacturers and markets laboratory equipment, diagnostic products, and medical instrument systems & reagents. The company operates its business through three segments—BD Medical, BD Life Sciences, and BD Interventional. In June 2020, BD announced the CE Mark and market launch of the BD Vacutainer UltraTouch Blood collection set.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=150226807
Be the first person to like this.
robert henric
posted a blog.
According to the new market research report “Electronic Trial Master File (eTMF) Systems Market by Component (Services, Software), End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations), Delivery Mode (On-Premise, Cloud-Based), and Region – Global Forecast to 2024″, published by MarketsandMarkets™, the eTMF systems market is projected to reach USD 1.8 billion by 2024 from USD 1.0 billion in 2019, at a CAGR of 12.7%
Report Objectives Coverd in Research;- To define, describe, segment, and forecast the eTMF systems market by delivery mode, component, end-user, and region- Will provide detailed information about the factors (such as drivers, restraints, opportunities, and challenges) influencing market growth- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94357456
The Factors such as rising adoption of eTMF systems, rising number of clinical trials, partnerships between biopharma companies and CROs, rising funding to support clinical trials, and the growth in the R&D spending by pharma & biotech companies are driving the growth of the eTMF Systems Market.
The cloud-based eTMF to register the highest CAGR during the forecast period
Based on delivery mode, the eTMF Systems Market is segmented into on-premise and cloud-based eTMF. The cloud-based eTMF segment is expected to register the highest CAGR during the forecast period. Growth in this segment can be attributed to the comparatively lower capital expenses & operational costs incurred in this model, alongside its scalability, flexibility, and affordability.
Cloud-based solutions help healthcare organizations share and integrate information from different locations, making the process of data gathering seamless. Moreover, these solutions are comparatively affordable to install and maintain as compared to on-premise solutions, thus contributing to the high growth and popularity of the cloud-based delivery model.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=94357456
North America dominated the Electronic Trial Master File Systems Market in 2018; this trend to continue during the forecast period
Geographically, the eTMF Systems Market is divided into North America, Europe, Asia Pacific, and the Rest of the World (RoW). The North American market accounted for the largest share of the Electronic Trial Master File (eTMF) Systems Market in 2018, primarily due to the increasing government funding for clinical research and a large number of clinical trials. Several major global players are also based in the US, owing to which the country has become a center of innovation in the eTMF Systems Market
Veeva Systems (US), Oracle Corporation (US), Phlexglobal Limited (UK), TransPerfect Global Inc. (US), Aurea Software (US), LabCorp (US), ePharmaSolutions (US), Wingspan Technology, Inc. (US), MasterControl (US), SureClinical, Inc. (US), Dell EMC (US), Paragon Solutions (US), PharmaVigilant (US), Mayo Clinic (US), Database Integrations, Inc. (US), CareLex (US), Ennov (France), Forte Research (US), Freyr (US), Montrium (US), NCGS Inc. (US), SAFE-BioPharma (US), SterlingBio Inc. (US), BIOVIA Corp. (US), and arivis AG (Germany) are the key players in the Electronic Trial Master File (eTMF) Systems Market.
Veeva Systems was the leading player in the electronic trial master file (eTMF) systems market in 2018. The company’s dominant position can be attributed to its solution, Veeva Vault eTMF. The company focuses on various inorganic and organic growth strategies such as solution deployments and expansions to maintain and enhance its market share. In the last three years, Veeva Systems has deployed its solutions at more than ten pharmaceutical companies, CROs, and other sites in the US to expand its user base with the development of innovative solutions. The company also has a strategic focus on expansions in growing emerging markets, such as the Middle East and Asia.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94357456
Be the first person to like this.
robert henric
posted a blog.
According to the new market research report “Women’s HealthCare Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) – Global forecast to 2024″, published by MarketsandMarkets™, is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period.
Report Objectives:- To define, describe, and forecast the women’s healthcare market on the basis of drug, application, and region- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, opportunities, and challenges)- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa- To profile the key players and analyze their market shares and core competencies
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136585329The Women’s Health Care Market growth is largely driven by the growing incidence of chronic health conditions among women, government initiatives to curb population growth, growing demand for contraceptives to prevent unintended pregnancies, and the growing focus on R&D by key players for the development of advanced products. On the other hand, the reluctance to use contraceptives is a major factor limiting the Women’s HealthCare Market growth.
Prolia is the largest and fastest-growing segment of the market.
Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. Prolia has shown a considerable year-on-year growth primarily due to increasing unit demand. Prolia has witnessed positive market growth owing to the increasing prevalence of postmenopausal osteoporosis in the US.
The postmenopausal osteoporosis segment is expected to grow at the highest CAGR during the forecast period.
On the basis of application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment is expected to grow at a higher CAGR during the forecast period. The growing prevalence of postmenopausal osteoporosis and a high risk of osteoporosis fractures are the prime factors that contribute towards the large share of this segment. Furthermore, the focus of pharmaceutical players on providing effective drugs for postmenopausal osteoporosis also supports the growth of this segment. The postmenopausal osteoporosis segment also holds the largest share of the market owing to these factors.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=136585329
North America commanded the largest share of the Women’s Health Care Market in 2019.
In 2018, North America was the largest and the fastest-growing regional market for women’s healthcare. The increasing median age of first-time pregnancies and the growing prevalence of PCOS and postmenopausal osteoporosis are the factors responsible for the growth of this regional segment. Furthermore, the growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending also support the growth of this market.
The prominent players in the global Women’s Health Care Market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=136585329
Be the first person to like this.